All In Biotech

Drug Trial Radar · NCT04804514

Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients

Phase 1/2a Study of KH001 in Dentin Hypersensitivity Patients

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jun 14, 2021

Primary completion

Mar 3, 2023

Study completion Mar 3, 2023

Sponsor

Lead sponsor
HysensBio Co., LtdIndustry
Sponsor type
Industry
First posted
Mar 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2a study in dentin hypersensitivity patients to assess the safety, tolerability, efficacy and pharmacokinetics of single and multiple doses of KH001.

Conditions

  • Dentin Sensitivity

Interventions

  • KH001Drug

    The study drug is applied to teeth

  • PlaceboDrug

    The placebo is applied to teeth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events(AEs)Time frame: up to 22 days and 36 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Dental Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.